ReNeuron (RNUGF) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research lowered shares of ReNeuron (OTCMKTS:RNUGF) from a buy rating to a hold rating in a research report sent to investors on Friday.

According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “

How to Become a New Pot Stock Millionaire

Shares of ReNeuron stock opened at $1.35 on Friday. The firm has a market cap of $42.72 and a price-to-earnings ratio of -1.35. ReNeuron has a 1-year low of $0.02 and a 1-year high of $1.35.

COPYRIGHT VIOLATION NOTICE: “ReNeuron (RNUGF) Downgraded by Zacks Investment Research to “Hold”” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3342220/reneuron-rnugf-downgraded-by-zacks-investment-research-to-hold.html.

About ReNeuron

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.

Get a free copy of the Zacks research report on ReNeuron (RNUGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ReNeuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Dinastycoin Price Reaches $0.0005
Dinastycoin Price Reaches $0.0005
Compcoin Market Capitalization Achieves $0.00
Compcoin Market Capitalization Achieves $0.00
Zacks: ATRION Co.  Given Average Recommendation of “Strong Sell” by Brokerages
Zacks: ATRION Co. Given Average Recommendation of “Strong Sell” by Brokerages
TechShares  Trading 1.3% Higher  Over Last Week
TechShares Trading 1.3% Higher Over Last Week
Abiomed  Expected to Post Earnings of $0.64 Per Share
Abiomed Expected to Post Earnings of $0.64 Per Share
$12.41 Billion in Sales Expected for PepsiCo  This Quarter
$12.41 Billion in Sales Expected for PepsiCo This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.